FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116572046> ?p ?o ?g. }

• W2116572046 endingPage "1414" @default.
• W2116572046 startingPage "1408" @default.
• W2116572046 abstract "PURPOSE The phosphatidylinositol 3-kinase/mammalian target of rapamycin (mTOR) signal transduction pathway controls cell proliferation and survival. Everolimus is an oral agent targeting raptor mTOR (mTORC1). The trial's goal was to determine the antitumor activity and safety of single-agent everolimus in patients with relapsed/refractory Waldenström macroglobulinemia (WM). PATIENTS AND METHODS Eligible patients had measurable disease (immunoglobulin M monoclonal protein > 1,000 mg/dL with > 10% marrow involvement or nodal masses > 2 cm), a platelet count more than 75,000 x 10(6)/L, a neutrophil count more than 1,000 x 10(6)/L, and a creatinine and bilirubin less than 2 x the laboratory upper limit of normal. Patients received everolimus 10 mg orally daily and were evaluated monthly. Tumor response was assessed after cycles 2 and 6 and then every three cycles until progression. Results Fifty patients were treated. The median age was 63 years (range, 43 to 85 years). The overall response rate (complete response plus partial remission [PR] plus minimal response [MR]) was 70% (95% CI, 55% to 82%), with a PR of 42% and 28% MR. The median duration of response and median progression-free survival (PFS) have not been reached. The estimated PFS at 6 and 12 months is 75% (95% CI, 64% to 89%) and 62% (95% CI, 48% to 80%), respectively. Grade 3 or higher related toxicities were observed in 56% of patients. The most common were hematologic toxicities with cytopenias. Pulmonary toxicity occurred in 10% of patients. Dose reductions due to toxicity occurred in 52% of patients. CONCLUSION Everolimus has high single-agent activity with an overall response rate of 70% and manageable toxicity in patients with relapsed WM and offers a potential new therapeutic strategy for this patient group." @default.
• W2116572046 created "2016-06-24" @default.
• W2116572046 creator A5000308170 @default.
• W2116572046 creator A5001453763 @default.
• W2116572046 creator A5002248011 @default.
• W2116572046 creator A5004152557 @default.
• W2116572046 creator A5023152679 @default.
• W2116572046 creator A5027394636 @default.
• W2116572046 creator A5032464400 @default.
• W2116572046 creator A5042578998 @default.
• W2116572046 creator A5043017271 @default.
• W2116572046 creator A5043526996 @default.
• W2116572046 creator A5044733637 @default.
• W2116572046 creator A5055454241 @default.
• W2116572046 creator A5055467873 @default.
• W2116572046 creator A5059729547 @default.
• W2116572046 creator A5070360113 @default.
• W2116572046 creator A5076611748 @default.
• W2116572046 creator A5081041356 @default.
• W2116572046 creator A5081299017 @default.
• W2116572046 creator A5082924494 @default.
• W2116572046 date "2010-03-10" @default.
• W2116572046 modified "2023-10-18" @default.
• W2116572046 title "Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia" @default.
• W2116572046 cites W1907858048 @default.
• W2116572046 cites W1910831415 @default.
• W2116572046 cites W1916527093 @default.
• W2116572046 cites W1976156505 @default.
• W2116572046 cites W1987173571 @default.
• W2116572046 cites W1995125949 @default.
• W2116572046 cites W1995735611 @default.
• W2116572046 cites W2009615948 @default.
• W2116572046 cites W2010397777 @default.
• W2116572046 cites W2012570443 @default.
• W2116572046 cites W2015975538 @default.
• W2116572046 cites W2032002112 @default.
• W2116572046 cites W2034902680 @default.
• W2116572046 cites W2046956055 @default.
• W2116572046 cites W2052664886 @default.
• W2116572046 cites W2062711303 @default.
• W2116572046 cites W2065322400 @default.
• W2116572046 cites W2065938303 @default.
• W2116572046 cites W2069645288 @default.
• W2116572046 cites W2077494567 @default.
• W2116572046 cites W2086126496 @default.
• W2116572046 cites W2086332514 @default.
• W2116572046 cites W2087861588 @default.
• W2116572046 cites W2091412133 @default.
• W2116572046 cites W2091721155 @default.
• W2116572046 cites W2114956843 @default.
• W2116572046 cites W2117582823 @default.
• W2116572046 cites W2118677643 @default.
• W2116572046 cites W2123323375 @default.
• W2116572046 cites W2130883918 @default.
• W2116572046 cites W2132155614 @default.
• W2116572046 cites W2145676206 @default.
• W2116572046 cites W2147649894 @default.
• W2116572046 cites W2149287539 @default.
• W2116572046 cites W2150026213 @default.
• W2116572046 cites W2150724746 @default.
• W2116572046 cites W2150945698 @default.
• W2116572046 cites W2153867442 @default.
• W2116572046 cites W2160542415 @default.
• W2116572046 cites W2188965426 @default.
• W2116572046 cites W2240525300 @default.
• W2116572046 cites W2263638048 @default.
• W2116572046 cites W2491492261 @default.
• W2116572046 cites W3190289852 @default.
• W2116572046 cites W4210983280 @default.
• W2116572046 cites W4233186950 @default.
• W2116572046 cites W4247589884 @default.
• W2116572046 cites W4293241248 @default.
• W2116572046 cites W4361865146 @default.
• W2116572046 doi "https://doi.org/10.1200/jco.2009.24.0994" @default.
• W2116572046 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2834498" @default.
• W2116572046 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20142598" @default.
• W2116572046 hasPublicationYear "2010" @default.
• W2116572046 type Work @default.
• W2116572046 sameAs 2116572046 @default.
• W2116572046 citedByCount "128" @default.
• W2116572046 countsByYear W21165720462012 @default.
• W2116572046 countsByYear W21165720462013 @default.
• W2116572046 countsByYear W21165720462014 @default.
• W2116572046 countsByYear W21165720462015 @default.
• W2116572046 countsByYear W21165720462016 @default.
• W2116572046 countsByYear W21165720462017 @default.
• W2116572046 countsByYear W21165720462018 @default.
• W2116572046 countsByYear W21165720462019 @default.
• W2116572046 countsByYear W21165720462020 @default.
• W2116572046 countsByYear W21165720462021 @default.
• W2116572046 countsByYear W21165720462022 @default.
• W2116572046 countsByYear W21165720462023 @default.
• W2116572046 crossrefType "journal-article" @default.
• W2116572046 hasAuthorship W2116572046A5000308170 @default.
• W2116572046 hasAuthorship W2116572046A5001453763 @default.
• W2116572046 hasAuthorship W2116572046A5002248011 @default.
• W2116572046 hasAuthorship W2116572046A5004152557 @default.
• W2116572046 hasAuthorship W2116572046A5023152679 @default.

• next